The Serum Institute of India hopes to launch Novavax’s Covid-19 vaccine ‘Covovax’ in India by September if it receives the required regulatory nod by the Centre, CEO Adar Poonawalla told CNBC-TV18.
Poonwalla said that the trials for the vaccines are in the advanced stage and are likely to conclude before November. The vaccine manufacturer can apply for licence before the trial concludes based on the global data available for the vaccine.
They are also planning to start a trial of Covovax for children in July. SII entered into an agreement to manufacture Novavax's vaccine named Covovax in September last year.
Novavax in a statement on June 14 stated that it's vaccine candidate showed 100% against moderate and severe Covid-19 infection and 90.4 percent efficacy overall.
Also Read | Calf serum in Covaxin? Govt and Bharat Biotech clarify